Filters

Pp-191 manufacturers

Filters

None products found

pp-191

Solution for injection

Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Non-syndromic retinitis pigmentosa (RP) — vision restoration in patients with advanced photoreceptor loss Clinical stage: BLA under rolling submission to FDA (pivotal Phase 2/3 data filed) Modality: Biological (AAV2-based optogenetic gene therapy) Mechanism / Target: AAV2 vector delivering multi-characteristic opsin (MCO) gene to degenerate retinal bipolar and ganglion cells; MCO protein restores light-responsiveness independent of remaining photoreceptors; mutation-agnostic mechanism Route / form: Single intravitreal injection Differentiation: First-in-class optogenetic gene therapy for RP; FDA RMAT Designation; mutation-agnostic (treats all genetic forms of RP unlike gene-specific therapies); BLA under rolling FDA submission 2025; single-injection treatment;
Manufacturer #39331
US-based clinical-stage company developing Rx gene therapy for vision restoration in inherited retinal degenerative conditions. Proprietary, gene-agnostic, light-activated approach does not require residual photoreceptor activity. Advancing through clinical trials across multiple retinal indications.

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.